Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-22
2008-07-22
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S112000
Reexamination Certificate
active
07402592
ABSTRACT:
Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a compound of Formulas 1 or 2, as described herein. The compounds of Formulas 1 and 2 are also useful for treating pain, and treating drug addiction, nicotine addiction, and/or obesity. The compounds can exist as individual stereoisomers, racemic mixtures, diastereomers and the like.
REFERENCES:
patent: 4922901 (1990-05-01), Brooks
patent: 4965074 (1990-10-01), Leeson
patent: 5187166 (1993-02-01), Kikuchi
patent: 5210076 (1993-05-01), Berliner
patent: 5212188 (1993-05-01), Caldwell
patent: 5227391 (1993-07-01), Caldwell
patent: 5242935 (1993-09-01), Lippiello
patent: 5583140 (1996-12-01), Bencherif
patent: 5597919 (1997-01-01), Dull
patent: 5604231 (1997-02-01), Smith
patent: 5616716 (1997-04-01), Dull
patent: 5663356 (1997-09-01), Ruecroft
patent: 5672601 (1997-09-01), Cignarella
patent: 5852041 (1998-12-01), Cosford
patent: 5853696 (1998-12-01), Elmaleh
patent: 5861423 (1999-01-01), Caldwell
patent: 5952339 (1999-09-01), Bencherif
patent: 5969144 (1999-10-01), London
patent: 6310043 (2001-10-01), Bundle
patent: 6638925 (2003-10-01), Czollner
patent: 2001/0056084 (2001-12-01), Allgeier
patent: 2002/0016371 (2002-02-01), Shytle
patent: 0 239 309 (1987-09-01), None
patent: 0 297 858 (1989-01-01), None
patent: 0 588 917 (1994-03-01), None
patent: 0 978 280 (2000-02-01), None
patent: 2 295 387 (1996-05-01), None
patent: WO 94/08992 (1994-04-01), None
patent: WO 96/30372 (1996-10-01), None
patent: WO 96/31475 (1996-10-01), None
patent: WO 96/36637 (1996-11-01), None
patent: WO 97/30998 (1997-08-01), None
patent: WO 98/25619 (1998-06-01), None
patent: WO 99/03859 (1999-01-01), None
patent: WO 99/21834 (1999-05-01), None
patent: WO 99/62505 (1999-12-01), None
patent: WO 99/65876 (1999-12-01), None
patent: WO 00/23424 (2000-04-01), None
patent: WO 01/36417 (2001-05-01), None
patent: WO 02/15662 (2002-02-01), None
patent: WO 02/16355 (2002-02-01), None
patent: WO 02/16356 (2002-02-01), None
patent: WO 02/16357 (2002-02-01), None
patent: WO 02/16358 (2002-02-01), None
patent: WO 02/17358 (2002-02-01), None
patent: WO 2004/016604 (2004-02-01), None
Yuen, Darren; Richardson, Robert M. A.; Fenton, Stanley S. A.; McGrath-Chong, Margaret E.; Chan, Christopher T. “Quotidian Nocturnal Hemodialysis Improves Cytokine Profile and Enhances Erythropoietin Responsiveness.” ASAIO Journal. 51(3):236-241, May/Jun. 2005. Abstract only.
Birch, et. al. “Reduction by Dissolving Metals” Australian Journal of Chemistry 1954, 7, 256-260.
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface, p. 41, 279-308.
(“Lithium Aluminum Hydride” Paquette, L. in Encyclopedia of Reagents for Organic Synthesis Online Posting Date: Oct. 15, 2004 2004 John Wiley & Sons, Ltd. “http://www.mrw.interscience.wiley.com/eros/articles/rl036/frame.html”.
Amundsen, L.H. et. al. J. Am. Chem. Soc. 1951, 73, 242-244.
F. Ivy Carroll “Epibatidine structure-activity relationships” Bioorganic & Medicinal Chemistry Letters 2004 14, 1889-1896.
Huabei Zhang, Hua Li, Qinqin M. “QSAR study of a large set of 3-pyridyl ethers as ligands of the a4b2 nicotinic acetylcholine receptor.” Journal of Molecular Graphics and Modelling 2007, 26, 226-235.
Desphande et. al.“Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin” PNAS 2006, 6332-6337.
Wong et. al. “Nicotine Promotes Colon Tumor Growth and Angiogenesis through b-Adrenergic Activation” Toxicological Sciences 2007, 97, 279-287.
Borisy et. al. “Systematic discovery of multicomponent therapeutics” PNAS 2003, 100, 7977-7982.
Grant R. Zimmermann “Multi-target therapeutics: when the whole is greater than the sum of the parts.” Drug Discovery Today 2007, 12, 34-42.
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface p. 1-15.
Adler, et al., “Normalization by Nicotine of Deficient Auditory Sensory Gating in the Relatives of Schizophrenics,”Biol. Psychiatry, 32(7): 607-616 (1992).
Afify, E.A., “Turnover of μ-opiod receptors in neuroblastoma cells,”Molecular Brain Research, 106: 83-87 (2002).
Arneric, S., et al., “Preclinical Pharmacology of ABT-418: A Prototypical Cholinergic Channel Activator for the Potential Treatment of Alzheimer's Disease,”CNS Drug Rev.1(1): 1-26 (1995).
Arneric, S., et al., “Cholinergic channel modulators as a novel therapeutic strategy for Alzheimer's disease,”Exp. Opin. Invest. Drugs, 5(1): 79-100 (1996).
Asaoka, M., et al., “A New Synthetic Route to Functionalized 2-Azabicyclo[2.2.2]Octane,”Heterocycles, 38(11): 2455-2462 (1994).
Bannon, A.W., et al., “ABT-594[(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: A Novel, Orally Effective Antinociceptive Agent Acting via Neuronal Nicotinic Acetylcholine Receptors: II. In Vivo Characterization,”J. Pharmaco.l Exp. Ther., 285(2): 787-794 (1998).
Bannon, A.W., et al., “Broad-Spectrum, Non-Opioid Analgesic Activity by Selective Modulation of Neuronal Nicotinic Acetylcholine Receptors,”Science, 279: 77-81 (1998).
Baron, J.A., “Cigarette smoking and Parkinson's Disease,”Neurology, 36:1490-1496 (1986).
Bencherif, M., and J. D. Schmitt, “Targeting Neuronal Nicotinic Receptors: a Path to New Therapies,”Current Drug Targets, 1(4): 349-357 (2002).
Bencherif, M., et al., “RJR-2403: A Nicotinic Agonist with CNS Selectivity I: In Vitro Characterization,”J. Pharmacol. Exper. Therapeutics, 279(3): 1413-1421 (1996).
Bencherif M. and R.J. Lukas, “Differential Regulation of Nicotinic Acetylcholine Receptor Expression by Human TE671/RD Cells Following Second Messenger Modulation and Sodium Butyrate Treatments,”Mol Cell Neurosci.,2(1): 52-65 (1991).
Bencherif, M., and R.J. Lukas, “Ligand Binding and Functional Characterization of Muscarinic Acetylcholine Receptors on the TE671/RD Human Cell Line,”J. Pharmacol. Exp. Ther., 257(3): 946-953 (1991).
Bennett, G.J., and Y.-K. Xie, “A peripheral mononeuropathy in rat that produced disorders of pain sensation like those seen in man,”Pain, 33: 87-107 (1988).
Boger, D.L., et al., “Synthetic Analgesics: Preparation of Racemic 6,7-Benzomorphans,”Tet. Lett., 23(44): 4559-4562 (1982).
Bok, Th. R., and W.N. Speckamp, “Synthesis and Conformational Analysis of EXO-and ENDO-7-Substituted-3-Azabicyclo[3.3.1.]Nonanes,”Tetrahedron, 35: 267-272 (1979).
Bok, Th. R. and Speckamp, W.N., “3-Azanoradamantanes,”Heterocycles, 12(3): 343-347 (1979).
Brioni, J.D., et al., “The Pharmacology of (−)-Nicotine and Novel Cholinergic Channel Modulators,”Adv. Pharmacol., 37: 153-214 (1997).
Calderon-Gonzalez, R., and R.F. Calderon-Sepulveda, “Tourette Syndrome Current Concepts,”Intern. Pediat., 8(2): 176-188 (1993).
Cheng, Yung-Chi, and W.H. Prusoff, “Relationship Between the Inhibition Constant (K1) and the Concentration of Inhibitor which Causes 50 Per Cent inhibition (I50) of an Enzymatic Reaction,”Biochem. Pharmacol., 22(23): 3099-3108 (1973).
Chiari, A., et al., “Sex Differences in Cholinergic Analgesia I: A Supplemental Nicotinic Mechanism in Normal Females,”Anesthesiology, 91(5): 1447-1454 (1999).
Clarke, P.B.S., et al., “Electrophysiological actions of nicotine on substantia nigra single units,”Br. J. Pharm., 85(4): 827-835 (1985).
D'amour, F.E., and D.L. Smith, “A Method for Determining Loss of Pain Sensation,”J. Pharmacol. Exp. Ther., 72: 74-79 (1941).
Damaj, M.I., et al., “The antinociceptive effects of α
Bhatti Balwinder S.
Breining Scott R.
Hawkins Gregory D.
Mazurov Anatoly
Miao Lan
Desai Rita
O'Dell David K
Targacept, Inc.
Womble Carlyle Sandridge & Rice PLLC
LandOfFree
Pharmaceutical compositions and methods for relieving pain... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions and methods for relieving pain..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions and methods for relieving pain... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2801192